diaDexus, VaxGen deal

The companies amended their previously announced merger. VaxGen will now own about 62% of the combined company, up from 39.1%, while diaDexus shareholders will own 38%, down from 60.9%. The move comes after diaDexus temporarily suspended the commercialization of its PLAC Test Turbidimetric Immunoassay (TIA) in May after heterophilic interference was observed in a small number of samples tested. The deal is expected to close next quarter. ...